Drug intelligence / Profile preview

ALV-200

Development stage: Preclinical
Lead developer: Alveus Therapeutics
Modality: Peptides
Administration: Subcutaneous

Overview

ALV-200 is a selective amylin receptor 3 (AMYR3) peptide agonist under development by Alveus Therapeutics for the treatment of obesity and metabolic disorders. Designed as a lipidated peptide for once-weekly subcutaneous administration, ALV-200 selectively targets the AMYR3 subtype to induce satiety and preserve lean body mass. This selectivity is intended to differentiate it from dual amylin and calcitonin receptor agonists (DACRAs) by minimizing calcitonin receptor (CTR)-mediated adverse effects, such as nausea and taste aversion. As of early 2026, the program is in the IND-enabling phase, with clinical trials expected to commence in 2027.

Other names: AMYR3 peptide agonistAMYR-3 peptide agonistAMYR 3 peptide agonist

Targets

AMY3 (Amylin receptor 3)

Beyond the preview

Go deeper on ALV-200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALV-200.

Explore the full profile